Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440476 | 0.87 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL414249 | 0.87 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL10956783 | 0.87 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL14665138 | 0.86 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| Hydrochloric Acid SCHEMBL7375378 | 0.86 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL1052527 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL1052525 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| Hydrochloric Acid SCHEMBL2084335 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HRH3CYP2D6 | |
| SCHEMBL14664041 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HRH3PARP1 | |
| SCHEMBL30979837 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HRH3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SLC6A2 3799/4885SLC6A4 3830/4885SLC6A3 3411/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | SLC6A2 3799/4885SLC6A4 3830/4885SLC6A3 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.